Charles River Laboratories International Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 5/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 189.43.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Charles River Laboratories International Inc's Score
Industry at a Glance
Industry Ranking
5 / 404
Overall Ranking
48 / 4592
Industry
Biotechnology & Medical Research
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
18
analysts
Buy
Current Rating
189.428
Target Price
+1.23%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Charles River Laboratories International Inc Highlights
StrengthsRisks
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Industry Leader
The company's revenue leads the industry, with the latest annual revenue totaling USD 4.05B.
Undervalued
The company’s latest PE is -126.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 52.25M shares, increasing 0.05% quarter-over-quarter.
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
Ticker SymbolCRL
CompanyCharles River Laboratories International Inc
CEOFoster (James C)
Websitehttps://www.criver.com/
FAQs
What is the current price of Charles River Laboratories International Inc (CRL)?
The current price of Charles River Laboratories International Inc (CRL) is 198.150.
What is the symbol of Charles River Laboratories International Inc?
The ticker symbol of Charles River Laboratories International Inc is CRL.
What is the 52-week high of Charles River Laboratories International Inc?
The 52-week high of Charles River Laboratories International Inc is 199.660.
What is the 52-week low of Charles River Laboratories International Inc?
The 52-week low of Charles River Laboratories International Inc is 91.861.
What is the market capitalization of Charles River Laboratories International Inc?
The market capitalization of Charles River Laboratories International Inc is 9.75B.
What is the net income of Charles River Laboratories International Inc?
The net income of Charles River Laboratories International Inc is 10.30M.
Is Charles River Laboratories International Inc (CRL) currently rated as Buy, Hold, or Sell?
According to analysts, Charles River Laboratories International Inc (CRL) has an overall rating of Buy, with a price target of 189.428.
What is the Earnings Per Share (EPS TTM) of Charles River Laboratories International Inc (CRL)?
The Earnings Per Share (EPS TTM) of Charles River Laboratories International Inc (CRL) is -1.530.